Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jn/132.6.1655S | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Social Vulnerability and Biological Aging in New York City: An Electronic Health Records-Based Study.
J Urban Health
January 2025
Department of Environmental Medicine and Climate Science, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1057, New York, NY, 10029, USA.
Chronological age is not an accurate predictor of morbidity and mortality risk, as individuals' aging processes are diverse. Phenotypic age acceleration (PhenoAgeAccel) is a validated biological age measure incorporating chronological age and biomarkers from blood samples commonly used in clinical practice that can better reflect aging-related morbidity and mortality risk. The heterogeneity of age-related decline is not random, as environmental exposures can promote or impede healthy aging.
View Article and Find Full Text PDFCharacterizing the Microstructural Transition at the Gray Matter-White Matter Interface: Implementation and Demonstration of Age-Associated Differences.
Neuroimage
January 2025
Department of Radiology, Columbia University Irving Medical Center, New York, NY; Department of Biomedical Engineering, Columbia University, New York, NY. Electronic address:
Background: The cortical gray matter-white matter interface (GWI) is a natural transition zone where the composition of brain tissue abruptly changes and is a location for pathologic change in brain disorders. While diffusion magnetic resonance imaging (dMRI) is a reliable and well-established technique to characterize brain microstructure, the GWI is difficult to assess with dMRI due to partial volume effects and is normally excluded from such studies.
Methods: In this study, we introduce an approach to characterize the dMRI microstructural profile across the GWI and to assess the sharpness of the microstructural transition from cortical gray matter (GM) to white matter (WM).
Vitritis following intravitreal faricimab: a retrospective monocentric analysis.
Graefes Arch Clin Exp Ophthalmol
January 2025
15-20 National Ophthalmologic Center, Paris, France.
Purpose: Intravitreal injections of anti-VEGF agents are considered as safe, with a very low rate of intraocular inflammations (IOI). Faricimab is a novel intravitreal bispecific antibody targeting both VEGF-A and angiopoietin-Tie2 independently. Despite a safe profile in randomized clinical trials, several real-life studies have reported cases of IOI.
View Article and Find Full Text PDFTrends of dental service utilization and expenditure in Taiwan from 2000 to 2020.
J Dent Sci
December 2024
Department of Health Care Administration, Chang Jung Christian University, Tainan, Taiwan.
Background: /purposeSince 1995, Taiwan's National Health Insurance (NHI) has offered a comprehensive dental coverage to over 99 % of the population. This study mainly analyzed the dental service utilization and expenditure trends by the gender, age, and service type and evaluated the resource allocation across different demographics from 2000 to 2020.
Materials And Methods: Nationwide NHI administrative data were used to assess the dental visit rates, average visits per user, and per capita expenditure by the gender, age, and 11 service categories for the years 2000, 2005, 2010, 2015, and 2020.
One-Year Outcomes in Subjects Developing Macular Neovascularization While Undergoing Avacincaptad Pegol Therapy for Geographic Atrophy.
Clin Ophthalmol
January 2025
Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USA.
Purpose: To assess the 12-month outcomes in subjects developing macular neovascularization (MNV) during intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Methods: This research was conducted as a case-controlled, retrospective study of AMD subjects undergoing IVA treatment for GA from two private practice institutions. Subjects were divided into 1) a Study Group of patients who developed MNV and then underwent anti-vascular endothelial growth factor (VEGF) therapy during the study period, and 2) a Control Group of patients who were complication-free during the study period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!